Utilisation of Angiox® in European Practice

The Medicines Company2,019 enrolled

Overview

The objective of this study is to determine utilisation patterns in patients receiving Angiox® in participating European centres. Additionally, through the collection of descriptive safety and outcomes data, this study will contribute to the Risk Management strategy for Europe

Study Type

OBSERVATIONAL

Enrollment

2,019

Conditions

Stable Angina (SA)NSTE-ACS (NSTEMI and UA)STEMI (STE-ACS)

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Eligible for, and receive treatment with Angiox®. * Willing and able to provide written informed consent to the use of their data in accordance with relevant local Data Protection laws, policies and regulations Exclusion Criteria: * Participation in other interventional clinical research studies involving the evaluation of investigational drugs, including Angiox®, or devices at the time of enrolment. * Patients not eligible for treatment for Angiox®.

Locations (2)

Centre Hospitalier Universitaire de Caen

Caen, France

Medizinische Klinik I Kardiologie/Pneumologie/Internistische

Rostock, Germany

Outcomes

Primary Outcomes

Posology and usage patterns of Angiox®: Dose(s) and time of bolus and infusion administered

Time frame: from hospital admission until hospital discharge, or 7 days after administration (which ever is earlier).

Secondary Outcomes

Death Myocardial infarction Unplanned revascularisation Stroke Major* and minor bleeding Thrombocytopenia Stent thrombosis Adverse events and serious adverse events

Time frame: measured in-hospital (prior to discharge), and at post-hospital discharge in outpatient as per local practice (30 days)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.